Factory 99% Atracurium Besylate Powder CAS 64228-81-5 Chemical Intermediate

• Customization: Available
• Powder: Yes
• Customized: Customized
• Model NO.: A992
• Certification: GMP, HSE, ISO 9001, USP, BP
• Suitable for: Elderly, Children, Adult
• State: Powder
• Purity: >99%
• Name: Atracurium Besylate
• CAS: 64228-81-5
• Appearance: White Powder
• Assay: 99%
• OEM: Available
• Sample: Available
• Suitable: Adult
• MOQ: 1g
• Function: Chemical Intermediate
• Transport Package: Foil Bag
• Specification: 99
• Trademark: /
• Origin: China
• Production Capacity: 10000 Kgs Per Month

Product Description

 

Product Name	Atracurium Besylate
Appearance	White Powder
CAS NO.	64228-81-5
Storage	Keep in a cool, dry, dark location

 

Atracurium besylate (CAS No. 64228-81-5) is a non-depolarizing neuromuscular blocking agent (NMBA) used to induce skeletal muscle relaxation during anesthesia or mechanical ventilation. It acts by competitively inhibiting nicotinic acetylcholine receptors at the neuromuscular junction, preventing nerve impulse transmission and resulting in muscle paralysis. Unlike some NMBAs, atracurium undergoes spontaneous degradation via Hofmann elimination (a pH- and temperature-dependent process) and ester hydrolysis, bypassing hepatic and renal metabolism, which reduces accumulation risks in patients with organ dysfunction.

 

1. General Anesthesia: Facilitates tracheal intubation and surgical muscle relaxation by providing a predictable onset and intermediate duration of action, tailored by adjusting dosage.
2. Mechanical Ventilation: Reduces respiratory muscle activity in critically ill patients, improving ventilation-perfusion matching and oxygenation.
3. Emergency and ICU Settings: Offers a rapid-onset alternative in scenarios where renal or hepatic function is compromised, avoiding drug accumulation.

1. Neuromuscular Blockade: Blocks acetylcholine binding at post-synaptic membranes, halting muscle contraction without affecting sensory or cognitive functions.
2. Spontaneous Degradation: Metabolized independently of organ function, ensuring predictable clearance and minimizing adverse effects related to accumulation.
3. Hemodynamic Stability: Minimal histamine release and lack of direct cardiovascular effects (e.g., bradycardia or hypotension) maintain stable circulation during administration.